Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Price Target at $4.25

Mersana Therapeutics, Inc. (NASDAQ:MRSN) has been given a consensus recommendation of “Buy” by the five brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $4.00.

MRSN has been the subject of several research reports. William Blair assumed coverage on shares of Mersana Therapeutics in a report on Thursday, February 6th. They set an “outperform” rating for the company. Wedbush reissued an “outperform” rating and set a $4.00 price target on shares of Mersana Therapeutics in a report on Monday, March 3rd.

Mersana Therapeutics Price Performance

Shares of NASDAQ MRSN opened at $0.46 on Thursday. The firm has a market cap of $57.21 million, a P/E ratio of -0.75 and a beta of 1.67. Mersana Therapeutics has a twelve month low of $0.43 and a twelve month high of $5.11. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 13.35. The company has a 50 day moving average of $0.59 and a 200 day moving average of $1.48.

Mersana Therapeutics (NASDAQ:MRSN) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The firm had revenue of $16.36 million during the quarter, compared to analysts’ expectations of $7.71 million. As a group, research analysts expect that Mersana Therapeutics will post -0.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in MRSN. US Bancorp DE purchased a new stake in shares of Mersana Therapeutics in the 3rd quarter worth $31,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Mersana Therapeutics during the 3rd quarter valued at approximately $34,000. China Universal Asset Management Co. Ltd. bought a new stake in Mersana Therapeutics during the 4th quarter worth approximately $37,000. Intech Investment Management LLC purchased a new position in Mersana Therapeutics during the third quarter valued at approximately $52,000. Finally, Quarry LP purchased a new position in Mersana Therapeutics during the third quarter valued at approximately $57,000. 93.92% of the stock is currently owned by institutional investors.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.